TR201900695T4 - HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER. - Google Patents

HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER. Download PDF

Info

Publication number
TR201900695T4
TR201900695T4 TR2019/00695T TR201900695T TR201900695T4 TR 201900695 T4 TR201900695 T4 TR 201900695T4 TR 2019/00695 T TR2019/00695 T TR 2019/00695T TR 201900695 T TR201900695 T TR 201900695T TR 201900695 T4 TR201900695 T4 TR 201900695T4
Authority
TR
Turkey
Prior art keywords
protein
hpv
terminal
hpv type
terminal part
Prior art date
Application number
TR2019/00695T
Other languages
English (en)
Turkish (tr)
Inventor
Misseri Yolande
Bridonneau Philippe
Goubier Anne
Original Assignee
Genkyotex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genkyotex filed Critical Genkyotex
Publication of TR201900695T4 publication Critical patent/TR201900695T4/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y406/00—Phosphorus-oxygen lyases (4.6)
    • C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
    • C12Y406/01001—Aodenylate cyclase (4.6.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/00695T 2012-07-23 2013-07-23 HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER. TR201900695T4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305898.4A EP2689786A1 (en) 2012-07-23 2012-07-23 HPV/CYAA-based chimeric proteins and their uses in the induction of immune responses against HPV infection and HPV-induced disorders

Publications (1)

Publication Number Publication Date
TR201900695T4 true TR201900695T4 (en) 2019-03-21

Family

ID=48832935

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00695T TR201900695T4 (en) 2012-07-23 2013-07-23 HPV / CYAA-BASED CHEMICAL PROTEINS AND THEIR USE IN INDUCING IMMUNE RESPONSE AGAINST HPV INFECTION AND HPV-INDUCED DISASTER.

Country Status (21)

Country Link
US (1) US9827302B2 (enExample)
EP (2) EP2689786A1 (enExample)
JP (1) JP6466328B2 (enExample)
KR (1) KR20150031487A (enExample)
CN (1) CN104736173B (enExample)
AU (1) AU2013295047B2 (enExample)
CA (1) CA2879999A1 (enExample)
DK (1) DK2874657T3 (enExample)
ES (1) ES2712647T3 (enExample)
HR (1) HRP20190108T1 (enExample)
HU (1) HUE042808T2 (enExample)
LT (1) LT2874657T (enExample)
MX (1) MX2015001021A (enExample)
PL (1) PL2874657T3 (enExample)
PT (1) PT2874657T (enExample)
RS (1) RS58313B1 (enExample)
RU (1) RU2015100212A (enExample)
SI (1) SI2874657T1 (enExample)
SM (1) SMT201900057T1 (enExample)
TR (1) TR201900695T4 (enExample)
WO (1) WO2014016312A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2690172A1 (en) * 2012-07-23 2014-01-29 Genticel CYAA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
EP3037103A1 (en) * 2014-12-23 2016-06-29 Genticel Immunotherapeutic vaccine comprising E7 proteins of HPV16 and HPV18 fused with CyaA, for use in subjects infected with HPV
EP3323424A1 (en) * 2016-11-17 2018-05-23 Cyanimal IP Cyaa polypeptides as immune enhancer
CA3109889A1 (en) * 2018-08-23 2020-02-27 Glaxosmithkline Biologicals Sa Immunogenic proteins and compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209817A (ja) 1988-02-17 1989-08-23 Yamaha Corp 浮動少数点形ディジタル・アナログ変換器
PT1188446E (pt) 2000-09-15 2009-11-10 Pasteur Institut Vectores proteinácios para a distribuição da molécula a células que expressam cd11b
EP1489092A1 (en) 2003-06-18 2004-12-22 Institut Pasteur Modified Bordetella adenylate cyclase comprising or lacking CD11b/CD18 interaction domain and uses thereof
PL1576967T3 (pl) * 2004-03-18 2008-03-31 Pasteur Institut Rekombinowane białko niosące epitopy ludzkiego wirusa brodawczaka wstawione w białko cyklazy adenylanowej lub jego fragment oraz jego zastosowania terapeutyczne
US8183007B2 (en) 2008-07-22 2012-05-22 Promega Corporation ADP detection based methods using adenylate cyclase and bioluminescence
EP2478915A1 (en) * 2011-01-24 2012-07-25 Genticel CyaA-carried polypeptide(s) and use to induce both therapeutic and prophylactic immune responses

Also Published As

Publication number Publication date
EP2874657B1 (en) 2018-10-17
RU2015100212A (ru) 2016-09-10
CA2879999A1 (en) 2014-01-30
JP2015524420A (ja) 2015-08-24
EP2689786A1 (en) 2014-01-29
JP6466328B2 (ja) 2019-02-13
CN104736173B (zh) 2019-02-05
EP2874657A1 (en) 2015-05-27
PL2874657T3 (pl) 2019-05-31
PT2874657T (pt) 2019-02-18
ES2712647T3 (es) 2019-05-14
DK2874657T3 (en) 2019-02-11
US9827302B2 (en) 2017-11-28
KR20150031487A (ko) 2015-03-24
SI2874657T1 (sl) 2019-03-29
RS58313B1 (sr) 2019-03-29
LT2874657T (lt) 2019-02-25
HUE042808T2 (hu) 2019-07-29
HK1208822A1 (en) 2016-03-18
CN104736173A (zh) 2015-06-24
SMT201900057T1 (it) 2019-02-28
US20150250867A1 (en) 2015-09-10
MX2015001021A (es) 2015-08-05
HRP20190108T1 (hr) 2019-03-22
WO2014016312A1 (en) 2014-01-30
AU2013295047A1 (en) 2015-02-05
AU2013295047B2 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
US11479605B2 (en) Homodimeric protein constructs
CN107434827B (zh) 用作诱导抗原特异性t细胞反应的免疫原性增强剂的融合蛋白
CN104640564B (zh) 分枝杆菌抗原疫苗
US11185580B2 (en) Compositions, methods and uses for improved human papilloma virus constructs
KR20160130216A (ko) 헤테로올리고머 미코박테리아 항원의 융합물
PH12013500050A1 (en) Anticancer fusion protein
JP2014504851A5 (enExample)
EA201790976A1 (ru) Терапевтические вакцины против hpv16
US20140234316A1 (en) Vaccibodies targeted to cross-presenting dendritic cells
EP2288380A2 (en) Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same
Tyler et al. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing
JP2015524403A5 (enExample)
KR102379951B1 (ko) 인플루엔자 핵단백질 백신
JP2015504052A5 (enExample)
CN107847575A (zh) 用于猪生殖与呼吸综合症及猪圆环病毒相关疾病的疫苗组合物
CA2888340C (en) Vaccine for preventing porcine edema disease
CN102311500B (zh) 一种抗病毒融合蛋白及其应用
RU2015100211A (ru) Химерные белки на основе cyaa, включающие гетерологичный полипептид, и их применение в индукции имунного ответа
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
Wang et al. Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
CN110746496B (zh) 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
RU2015100212A (ru) Химерные белки на основе hpv/cyaa и их применение в индукции имунного ответа против hpv-инфекции и расстройств, вызываемых hpv
CN101531719B (zh) 一种禽流感基因工程多肽抗原
JP2015524420A5 (enExample)